The trajectory of companies tied to iconic drugs like Viagra presents a complex investment picture. While the initial surge of copyright, fueled by Viagra's extraordinary popularity, generated substantial profits , the loss of exclusivity in key markets has introduced significant risk . Investors are now assessing the impact of lower-cost alternati